MedTrace Logo

Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK

NCT03606655 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-01-13

No results posted yet for this study

Summary

Tobacco smoking is the leading cause of head and neck cancer in the United States. Smoking cessation remains a challenge for many head/neck cancer survivors, indicating a need for development of more effective smoking cessation interventions. Kava's properties as a proven anxiolytic and carcinogen detoxifier warrant an investigation of its efficacy as an innovative smoking cessation aid. Kava may also influence carcinogen (NNK specifically) metabolism to help reduce carcinogenesis risk.

Conditions

  • Kava on the Metabolism of Nicotine and NNK

Interventions

DRUG

Kava

Kava: 75 mg three times daily (3 capsules)

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Natalie Silver, MD · University of Florida

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2020-10-31
Completion
2021-01-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03606655 on ClinicalTrials.gov